To evaluate whether CXCL13+ CD4+ and CD8+ T cell subsets can predict recurrence in CESC patients undergoing CCRT, we first identified the intersection of signature genes from these two cell subsets, yielding a total of 15 genes (Fig. 7a). The gene discussed is CD4; the disease is cervical squamous cell carcinoma.